Jim Smith
Guest
Jim Smith
Guest
Merck said today that the FDA has given consent to review a supplemental Biologics License Application (sBLA) for KEYTRUDA for the treatment of non-Hodgkin lymphoma. http://alph.st/bb41cf87
I have the top territory in Merck, world wide and you know why? My specialists have been treating this form of cancer since the were given the initial data. Laggers never win!Merck said today that the FDA has given consent to review a supplemental Biologics License Application (sBLA) for KEYTRUDA for the treatment of non-Hodgkin lymphoma. http://alph.st/bb41cf87
No one would ever fire me for I am the franchise. Only the deli crowd gets terminated. I don't get all the stage time and awards for nothing.Stick to your indications or get fired.